HPMA copolymer-antibody constructs in neoplastic treatment: an overview of therapeutics, targeted diagnostics, and drug-free systems

0525628 - ÚMCH 2021 RIV NL eng J - Článek v odborném periodiku
Randárová, Eva - Kudláčová, Júlia - Etrych, Tomáš
HPMA copolymer-antibody constructs in neoplastic treatment: an overview of therapeutics, targeted diagnostics, and drug-free systems.
Journal of Controlled Release. Roč. 325, 10 September (2020), s. 304-322. ISSN 0168-3659. E-ISSN 1873-4995
Grant CEP: GA MŠMT(CZ) ED1.1.00/02.0109; GA MŠMT(CZ) LQ1604; GA ČR(CZ) GA19-01417S; GA ČR(CZ) GJ19-00956Y; GA MŠMT(CZ) LTAUSA18083
Institucionální podpora: RVO:61389013
Klíčová slova: HPMA copolymers * antibody * APDC
Obor OECD: Polymer science
Impakt faktor: 9.776, rok: 2020
Způsob publikování: Omezený přístup
https://www.sciencedirect.com/science/article/pii/S0168365920303758?via%3Dihub

In the past decades, nanosized drug delivery systems based on N-(2-hydroxypropyl)methacrylamide copolymers (pHPMA) have gained increasing attention in nanomedicine field due to their hydrophilicity, versatility, biocompatibility, non-toxicity, and non-immunogenicity. Indeed, pHPMA nanosystems with various controlled drug release capabilities inside targeted tissues or cells have been intensively studied. This paper summarizes recent advances in the design and application of pHPMA conjugates with specific antibodies or their fragments, focusing predominantly on the systems for the cancer therapy, particularly, the mechanisms of action of therapeutic antibodies, the approaches of their modification and subsequent attachment of pHPMA and their conjugates with diverse active moieties. Finally, we highlight the major biomedical applications of these antibody-polymer-drug conjugates and consider directions of possible development over the coming decade.
Trvalý link: http://hdl.handle.net/11104/0309892